FEMALE SEXUAL DYSFUNCTION (HSDD Hypoactive Sexual Desire Disorder) Hypoactive Sexual Desire Disorder Definition and Prevalence: HSDD: Absence/decrease in sexual thoughts/fantasies + lack of sexual response desire Prevalence: 8121 TP3T in premenopausal women, 12261 TP3T in postmenopausal women Impact: Significant personal distress, relationship conflicts PT-141 Pivotal Clinical Studies: RECONNECT Study (Kingsberg et al., 2019): Design: Phase 3 RCT, n=1,247 premenopausal women with HSDD Dosage: 1.75 mg SC on-demand (45 min before anticipated sexual activity) Duration: 24 weeks Primary outcomes: Satisfying Sexual Events (SSE) +1.2 vs +0.4 placebo (p MC1R (lower pigmentation) Tanning: minimal/absent therapeutic doses Appetite: Minimal effects pro-sexual doses Duration: 6-12h (more controllable profile) Clinical Development: FDA Approval (Melanotan II not approved) What do studies in postmenopausal models/populations document

Concentraciones Tpicas Rango comn: 0,1%-2% de GHK-Cu en sueros y cremas para uso general en la piel o aplicacin en el cabello y el cuero cabelludo
HUBERMAN: And the first thing is that injury seems to be important
[DOI] [Google Scholar] Colby B
Standalone diet trackers and fitness applications are excluded
Symptoms: You should feel energetic, have a stable mood, and healthy digestion